IL22 and psoriasis: T cell-associated gene (LCK and TRCB1) and inflammatory gene (IL17, IL22 and IFN-γ) activity remains increased in the skin after psoriasis lesions, at least three months after the onset of the treatment with TNF-α inhibitors [5,6].